drugset / Trial / NCT04167540
GDNF Gene Therapy for Parkinson's Disease
Phase 1
Active not recruiting
11 enrolled
Brain Neurotherapy Bio, Inc.
AskBio Inc · collabCalifornia Institute for Regenerative Medicine (CIRM) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2023-10-17
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AAV2-GDNF | Gene therapy (AAV / viral vector) | — | Other |